BIAL bids to get US-registered Parkinson’s treatment authorised for Europe

Portuguese pharmaceutical company Bial is leading a bid to receive authorisation in Europe for a medication to treat Parkinson’s disease. The sub-lingual apomorphine treatment is sold under the name Kynmobi by Sunovion Pharmaceuticals in the United States. It is a dopamine agonist – meaning it is a medication that mimics dopamine, the brain chemical responsible for normal movement. Kynmobi is meant to be used as needed for “off” time in the disease – when sufferers are experiencing tremors and difficulty with movements . BIAL says it hopes to present its request for licensing later this year.